Back to results
US 10,519,158 B2Granted
Inhibiting the transient receptor potential A1 ion channel
AssigneeEli Lilly and Company
InventorsBertrand L. Chenard, Xinyuan Wu
Life of this patent
Estimating the term…
Abstract
The present invention relates to pharmaceutical compounds of the Formula (I), or a pharmaceutically acceptable salt or composition thereof, and methods of their use for the treatment of pain, respiratory conditions, as well as inhibiting the Transient Receptor Potential A1 ion channel (TRPA1).
Claims20
A compound of Formula (I):
- or a pharmaceutically acceptable salt thereof, wherein:
- R1 is
- R2 is is methyl;
- R3 is
- R4 is independently H, methyl, ethyl, propyl, cyano, methoxy, chlorine, fluorine, bromine, —CF3, —CF2,
- R5 is independently H, —CF3, cyanomethyl, bromine, chlorine, fluorine, methyl, ethyl, isopropyl, cyano, keto,
- R6 is H;
- and
- R8 is H, methyl, ethyl, or CF3.
6 more elements
A compound of the formula:
- or a pharmaceutically acceptable salt thereof.
A compound of the formula:
- or a pharmaceutically acceptable salt thereof.
A compound of the formula:
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.